Last reviewed · How we verify
Herceptin
At a glance
| Generic name | Herceptin |
|---|---|
| Also known as | Trastuzumabum (European Union), Trastuzumab (United States), Trastuzumab, trastuzumab, Trastuzumab (EU) |
| Sponsor | National Cancer Institute (NCI) |
| Target | Receptor tyrosine-protein kinase erbB-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- HER2-positive carcinoma of breast
- HER2-positive colon cancer
- HER2-positive rectal cancer
- HER2-positive salivary gland tumors
- Human epidermal growth factor 2 positive gastric cancer
- Secondary malignant neoplasm of female breast
- Secondary malignant neoplasm of stomach
Common side effects
- Alopecia
- Nausea
- Infusion/Administration Related Reactions (ARRs)
- Neutropenia
- Diarrhea
- Asthenia
- Fatigue
- Vomiting
- Myalgia
- Decreased Appetite
- Stomatitis
- Arthralgia
Serious adverse events
- Febrile Neutropenia
- Leukopenia
- Hypertension
- Left Ventricular Dysfunction
- Irregular Menstruation
- Granulocytopenia
- Amenorrhea
- Cellulitis
- Bronchitis
- Grade 3 Infusion/Administration Related Reactions
Key clinical trials
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (PHASE1)
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (PHASE1)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
- Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |